Skip to main content
. 2021 Dec 1;13(1):107–116. doi: 10.1111/1759-7714.14232

FIGURE 2.

FIGURE 2

(a) Progression‐free survival during treatment with crizotinib in crizotinib‐resistant patients (n = 52). (b) Time to treatment failure during treatment with crizotinib in the overall population (n = 61). (c) Progression‐free survival during treatment with alectinib in crizotinib‐resistant patients (n = 52). (d) CNS time to progression during treatment with alectinib in crizotinib‐resistant patients (n = 35)